Sharon Harig
Pulmonary Disease · Merrillville, INNPI 1770585861
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,674 of the $2,097 with a category attached, or 79.9%. 21 manufacturers reported payments, led by Boehringer Ingelheim at 27.0% of the total. Reporting peaked in 2021 at $1,137 and has fallen 74.0% since, to $296 in 2022. That places this record below the midpoint for pulmonary disease clinicians in IN, where the typical reported total is $2,226.
Across 75 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$566
- AstraZeneca$298
- Mylan Specialty L.p.$227
- Pfizer$174
- Sanofi$151
- Genentech USA, Inc.$125
- plus $556 from 15 others
Across 1 payment — averaging $0.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1
What the payments were for
- Consulting fees$42020%
- Food & beverage$1,67480%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $566 |
| AstraZeneca | 9 | $298 |
| Mylan Specialty L.p. | 13 | $227 |
| Pfizer | 12 | $174 |
| Sanofi | 4 | $151 |
| Genentech USA, Inc. | 1 | $125 |
| EKOS Corporation | 1 | $93 |
| GSK | 6 | $93 |
| Johnson & Johnson | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Advanced Respiratory, Inc | 2 | $43 |
| United Therapeutics Corporation | 3 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Shionogi Inc | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Circassia Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Insmed, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $12 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,097 in reported general payments places this provider in the 45th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Merrillville
- Hakam SafadiMerrillville$24K
- Bilal SafadiMerrillville$13K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.